Business
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI™ (maralixibat) oral solution - Six-year analysis showing significant improvement in
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI™ (maralixibat) oral solution\n\n- Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p","length":425,"tagName":"div"}]